Select Your Location:
Global
France
Switzerland DE | FR | IT
Italy

MAIC: Comparison of efficacy between BTKis in R/R CLL

Disease State: Hematologic malignancies

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology.

Video
26 May 2025

A summary of 12 studies from ASH 2024 addressing the use of BTK inhibitors, Bcl-2 inhibitors, BTK degraders, and other emerging therapies for B-cell malignancies.

Slide-Kit
26 May 2025
Please login or register to access the download

BGB-3111-215 (NCT04116437) is a Phase 2 study evaluating the safety of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Reading
23 May 2025